News | May 30, 2023
Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr
The company reported lifetime high EBIDTA of Rs. 250 crores
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated
